Skip to main content

Retinitis Pigmentosa (RP)

3
Pipeline Programs
7
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
2100%
+ 4 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Nacuity Pharmaceuticals
1 program
1
N-acetylcysteine amidePhase 31 trial
Active Trials
NCT07290530Not Yet Recruiting80Est. Dec 2028
Biocorp
BiocorpFrance - Issoire
1 program
1
Intravitreal Injection of UltevursenPhase 2RNA Therapeutic1 trial
Active Trials
NCT06627179Recruiting81Est. Dec 2027
Zhongmou Therapeutics
1 program
1
ZM-02Phase 1/21 trial
Active Trials
NCT07282457Not Yet Recruiting21Est. Dec 2031
Labcorp
LabcorpBURLINGTON, NC
1 program
ACE RetinoPHASE_1_21 trial
Active Trials
NCT06787482Recruiting100Est. Dec 2025
jCyte
jCyteCA - Newport Beach
1 program
human retinal progenitor cellsPHASE_1_21 trial
Active Trials
NCT02320812Completed28Est. Jul 2017
Thea Pharma
Thea PharmaMA - Waltham
1 program
Intravitreal Injection of UltevursenPHASE_2RNA Therapeutic

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Nacuity PharmaceuticalsN-acetylcysteine amide
BiocorpIntravitreal Injection of Ultevursen
Zhongmou TherapeuticsZM-02
LabcorpACE Retino
jCytehuman retinal progenitor cells

Clinical Trials (5)

Total enrollment: 310 patients across 5 trials

NCT07290530Nacuity PharmaceuticalsN-acetylcysteine amide

24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Start: Jun 2026Est. completion: Dec 202880 patients
Phase 3Not Yet Recruiting
NCT06627179BiocorpIntravitreal Injection of Ultevursen

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Start: Dec 2024Est. completion: Dec 202781 patients
Phase 2Recruiting
NCT07282457Zhongmou TherapeuticsZM-02

Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

Start: Jun 2026Est. completion: Dec 203121 patients
Phase 1/2Not Yet Recruiting
NCT06787482LabcorpACE Retino

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Start: Nov 2024Est. completion: Dec 2025100 patients
Phase 1/2Recruiting
NCT02320812jCytehuman retinal progenitor cells

Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

Start: Jun 2015Est. completion: Jul 201728 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 310 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.